Article Text

Download PDFPDF
Performance evaluation and clinical impact of the Oncomine Myeloid Research Assay for gene expression analysis in myeloid haematologic malignancies
  1. Min Ji Jeon1,
  2. Eun Sang Yu1,
  3. Dae Sik Kim1,
  4. Chul Won Choi1,
  5. Ha Nui Kim2,
  6. Jeong Ah Kwon2,
  7. Soo-Young Yoon2,
  8. Jung Yoon2
  1. 1Division of Hematology-Oncology, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea (the Republic of)
  2. 2Department of Laboratory Medicine, College of Medicine, Korea University, Seoul, Korea (the Republic of)
  1. Correspondence to Dr Jung Yoon, Korea University, Seongbuk-gu, Korea (the Republic of); yoteamoati{at}naver.com

Abstract

Aim Gene expression analysis facilitates the detection of diagnostic and prognostic biomarkers for myeloid haematological malignancies. The Oncomine Myeloid Research Assay (OMA; Thermo Fisher Scientific, Massachusetts, USA) provides a comprehensive analysis of gene expression of five target genes, along with gene alteration and fusion. Here, we present the performance of the OMA for gene expression analysis.

Methods In total, 53 RNA samples from patients diagnosed with acute myeloid leukaemia (AML) or myelodysplastic syndrome were included. Of these 53 samples, 3 were evaluated for reproducibility and 50 were evaluated for comparison with RNA-sequencing (RNA-seq). The prognostic impact of the gene expression profile produced by both OMA and RNA-seq in AML was investigated using follow-up data from 33 patients with AML.

Results The OMA showed good intrarun and interrun reproducibility. Compared with the RNA-seq results, high correlations were found in BAALC, MECOM and WT1 (all r>0.9), with moderate correlations in MYC (r=0.75, p<0.001) and SMC1A (r=0.42, p=0.002). The agreement between OMA and RNA-seq in classifying the dysregulated expression group was almost perfect, except for SMC1A (κ=0.175). Among these five genes, only BAALC showed a significant clinical impact in patients with AML. Patients with high BAALC expression showed significantly shorter overall survival based on both OMA (p=0.037) and RNA-seq (p=0.003).

Conclusions OMA gene expression analysis offers reproducible and accurate gene expression data for most targeted genes and demonstrates the utility of BAALC expression as a prognostic marker in AML.

  • Leukemia, Myeloid
  • Myelodysplastic Syndromes
  • Biomarkers, Tumor
  • Diagnostic Techniques and Procedures

Data availability statement

All data relevant to the study are included in the article or uploaded as online supplemental information.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

All data relevant to the study are included in the article or uploaded as online supplemental information.

View Full Text

Footnotes

  • Handling editor Runjan Chetty.

  • Contributors MJJ and JY designed the study. ESY, DSK and CWC performed clinical analysis and HNK, JAK and S-YY performed diagnostic analysis. JY carried out data analysis. MJJ and JY wrote the manuscript. JY is responsible for the overall content as the guarantor.

  • Funding This study was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (2022R1G1A1007629) and a grant funded by Korea University (K2023141).

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.